Panelists discuss how quadruplet regimens show improved efficacy over triplet regimens without significantly increased safety concerns, with anti-CD38 antibodies being well tolerated and NCCN ...

DataM Intelligence | competitive Intelligence Explore the evolving Multiple Myeloma market: drug innovations, emerging therapies, and key p ...

During a live event, Binod Dhakal, MD, and participants discussed their experience using selinexor in the second line and ...

Arndt Schottelius, MD PhD, CEO, commented: "We are delighted to welcome Stefan to Maxion at this pivotal time in our ...

Cambridge, UK-based Maxion Therapeutics today announced the appointment of Dr Stefan Härtle as chief development officer, ...

DataM Intelligence | competitive Intelligence ITP affects 2–5/100k yearly. New therapies like BTK, FcRn blockers aim for lasting remission, ...

Back in 2019, the companies teamed up to develop a successor to their multiple myeloma blockbuster Darzalex, an anti-CD38 antibody. The deal gave J&J the option to license HexaBody-CD38—which ...

The Phase 2 expansion Part B of the study assessed the objective response rate (primary endpoint) of intravenous HexaBody-CD38 versus subcutaneous daratumumab in patients with anti-CD38 antibody- ...

Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant Approval based on positive results from the IMROZ phase 3 study ...

With the expanded marketing authorization, Sarclisa is the first anti-CD38 therapy in combination with VRd in this patient population in the EU. Olivier Nataf, global head of oncology at Sanofi, said: ...

With the expanded marketing authorization, Sarclisa is the first anti-CD38 therapy in combination with VRd in this patient population in the EU. Olivier Nataf. Global Head of Oncology at Sanofi “While ...

Aim 1: Elucidate the role of CD38 in maintaining viability and cell activation of innate and adaptive immune cell subsets in tumour co-culture models. Aim 2: Characterize the tumour immune landscape ...